Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor (EGFR) inhibitor erlotinib in combination with gemcitabine was especially efficient in a pancreatic ductal adenocarcinoma (PDAC) subgroup of patients developing skin toxicity. However, EGFR expression was not...

Full description

Bibliographic Details
Main Authors: Laura Conradt, Klaus Godl, Christoph Schaab, Andreas Tebbe, Stefan Eser, Sandra Diersch, Christoph W. Michalski, Jörg Kleeff, Angelika Schnieke, Roland M. Schmid, Dieter Saur, Günter Schneider
Format: Article
Language:English
Published: Elsevier 2011-11-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558611800898

Internet

http://www.sciencedirect.com/science/article/pii/S1476558611800898

Similar Items